Investigating the role of amylin in diabetic nerve damage
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
This study is trying to see if the levels of a hormone called amylin are linked to nerve damage in people with Type-2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kentucky Academic / other |
| Locations | 2 sites (Lexington, Kentucky and 1 other locations) |
| Trial ID | NCT03481283 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between amylin levels and the severity of peripheral neuropathy in individuals with Type-2 diabetes. Researchers will collect blood and skin biopsy samples from participants to analyze amylin presence in the upper extremities. Additionally, patient responses to sensory stimuli such as heat, cold, and pressure will be measured to assess neuropathy symptoms. The study seeks to clarify the potential role of amylin in microvascular damage associated with diabetes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Type-2 diabetes who exhibit mild-to-severe peripheral neuropathy.
Not a fit: Patients who do not have a diagnosis of Type-2 diabetes or show normal nerve conduction velocity may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the mechanisms of diabetic peripheral neuropathy and potential therapeutic targets.
How similar studies have performed: While the specific role of amylin in diabetic peripheral neuropathy is not extensively studied, related research on amylin's effects in diabetes has shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has been diagnosed with Type-2 Diabetes. * Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests. Exclusion Criteria: * Subject has not been diagnosed with Type-2 Diabetes. * Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
Where this trial is running
Lexington, Kentucky and 1 other locations
- UK Robert Straus Behavioral Science Laboratory — Lexington, Kentucky, United States (Active_not_recruiting)
- University of Kentucky - Kentucky Neuroscience Institute — Lexington, Kentucky, United States (Recruiting)
Study contacts
- Principal investigator: John T Slevin, M.D., M.B.A. — University of Kentucky Department of Neurology
- Study coordinator: Rani Priyanka Vasireddy, MBBS, MHA
- Email: rvasireddy@uky.edu
- Phone: 859-218-5076
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.